Rapamycin and longevity: what the evidence shows.

Rapamycin occupies an unusual place: a molecule with genuinely striking laboratory findings, and at the same time one whose use for human longevity remains investigational.

Why scientists find it interesting

Rapamycin acts on a cellular pathway known as mTOR, central to growth, metabolism, and the cellular housekeeping process called autophagy. In a range of model organisms, modulating this pathway has produced some of the most consistent lifespan-extension findings in aging research. That track record is why the molecule is taken seriously.

What is established — and what is not

Rapamycin is an approved medication for specific, non-longevity uses, so its pharmacology in humans is reasonably well understood. What is not established is that it extends healthy lifespan in humans, or what dose and schedule would do so safely if it did. Active research is underway. The honest evidence rating for the longevity application is “preclinical”.

How a careful practice treats it

An honest practice can find rapamycin scientifically fascinating and still decline to present it as a proven longevity therapy. Holding both at once — genuine interest and evidentiary discipline — is the correct posture for a molecule at this stage.